ADIL Director Wendy Young Receives 25,666-Share Award

What Happened
Wendy B. Young, a director of Adial Pharmaceuticals, Inc. (ADIL), was granted a derivative award of 25,666 shares reported on 2026-09-17. The award is reported at $0.00 (no cash paid at grant), and the filing records the acquisition as a derivative grant rather than an open‑market purchase or sale. Per the filing, 2,138 of the shares vested immediately on the stockholder approval date; the remaining 23,528 shares vest in substantially equal installments over a 33‑month period beginning October 12, 2026.

Key Details

• Transaction date: 2026-09-17; reported on Form 4 filed 2026-09-21 (filed within the two-business-day window).
• Transaction type: Award/Grant (derivative); 25,666 shares at $0.00.
• Immediate vesting: 2,138 shares vested on the stockholder approval date (9/17/2026).
• Remaining vesting: 23,528 shares vest in equal installments over 33 months, starting 10/12/2026.
• Origin: Board approved the option grant on 6/11/2026 and the grant was issued 6/12/2026 subject to stockholder approval; stockholders approved the related plan amendment on 9/17/2026 (triggering the immediate vesting).
• Shares owned after transaction: Not specified in the provided filing excerpt.

Context
This was a derivative grant/award (not a cash purchase or sale). The filing reflects issuance and vesting terms tied to a plan amendment that required and received shareholder approval; immediate partial vesting resulted from that approval. For retail investors: grants and scheduled vesting signal compensation alignment but are not direct market buys — they do not necessarily indicate insider buying/selling intent.